Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02654678

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Ethicare GmbH (from the registry)
Registry
  • NCT NCT02654678
  • EudraCT 2015-002397-21
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria, Hungary, Netherlands, Serbia, United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02654678. Allocation not applicable; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2018-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril
Acronym
LENA-WP10
Condition
Heart Failure
Condition
Dilated Cardiomyopathy
Condition
Congenital Heart Disease
Intervention (Drug)
Enalapril Orodispersible Minitablet
Lead sponsor
Ethicare GmbH (class: industry)

Record details

Record id
cardio:ct-nct02654678
Content hash
830c9abe4f89725ff59205f9bd67caccbebee151e40c35d6f3f5dfc7514bdd4a